{"title":"新型β-石竹烯衍生物通过ros介导的细胞凋亡途径作为潜在抗癌药物的设计、合成和生物学评价。","authors":"Zhiwei Wang, Yang Chen, Anjie Huang, Hui Wen, Yetian Wu, Xingjun Xu, Zhongjing Qiao, Liangyu Chen, Yaopeng Zhao and Xinmiao Liang","doi":"10.1039/D4MD00951G","DOIUrl":null,"url":null,"abstract":"<p >As a top-three cancer in global incidence and mortality, colorectal cancer (CRC) urgently demands novel treatments. β-Caryophyllene (β-CP) and its derivatives, a class of sesquiterpenoids with broad anticancer potential, were structurally optimized in this study to enhance efficacy against CRC. Among the synthesized derivatives, <strong>AC-7</strong> exhibited potent cytotoxicity and selectivity in HT-29 cells (IC<small><sub>50</sub></small> = 3.09 μM, SI = 6.1), comparable to 5-fluorouracil (5-FU, IC<small><sub>50</sub></small> = 3.63 μM, SI = 0.4). Network pharmacology and gene enrichment analyses indicated that apoptosis, autophagy, ROS, and NF-κB were key downstream pathways of <strong>AC-7</strong>, which were later validated experimentally. <strong>AC-7</strong> arrested the cell cycle in the G0/G1 phase, promoted autophagy and apoptosis. ROS were identified as having a central role in regulating these related pathways. <em>In vivo</em> studies revealed the significant antitumor and DNA damage activity of <strong>AC-7</strong> in a nude mouse model. These findings suggest that <strong>AC-7</strong> is a promising candidate for anti-CRC therapy, acting through the ROS-mediated apoptosis pathway.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":" 7","pages":" 3174-3189"},"PeriodicalIF":3.5970,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Design, synthesis and biological evaluation of novel β-caryophyllene derivatives as potential anti-cancer agents through the ROS-mediated apoptosis pathway†\",\"authors\":\"Zhiwei Wang, Yang Chen, Anjie Huang, Hui Wen, Yetian Wu, Xingjun Xu, Zhongjing Qiao, Liangyu Chen, Yaopeng Zhao and Xinmiao Liang\",\"doi\":\"10.1039/D4MD00951G\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >As a top-three cancer in global incidence and mortality, colorectal cancer (CRC) urgently demands novel treatments. β-Caryophyllene (β-CP) and its derivatives, a class of sesquiterpenoids with broad anticancer potential, were structurally optimized in this study to enhance efficacy against CRC. Among the synthesized derivatives, <strong>AC-7</strong> exhibited potent cytotoxicity and selectivity in HT-29 cells (IC<small><sub>50</sub></small> = 3.09 μM, SI = 6.1), comparable to 5-fluorouracil (5-FU, IC<small><sub>50</sub></small> = 3.63 μM, SI = 0.4). Network pharmacology and gene enrichment analyses indicated that apoptosis, autophagy, ROS, and NF-κB were key downstream pathways of <strong>AC-7</strong>, which were later validated experimentally. <strong>AC-7</strong> arrested the cell cycle in the G0/G1 phase, promoted autophagy and apoptosis. ROS were identified as having a central role in regulating these related pathways. <em>In vivo</em> studies revealed the significant antitumor and DNA damage activity of <strong>AC-7</strong> in a nude mouse model. These findings suggest that <strong>AC-7</strong> is a promising candidate for anti-CRC therapy, acting through the ROS-mediated apoptosis pathway.</p>\",\"PeriodicalId\":88,\"journal\":{\"name\":\"MedChemComm\",\"volume\":\" 7\",\"pages\":\" 3174-3189\"},\"PeriodicalIF\":3.5970,\"publicationDate\":\"2025-05-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"MedChemComm\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://pubs.rsc.org/en/content/articlelanding/2025/md/d4md00951g\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"MedChemComm","FirstCategoryId":"1085","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2025/md/d4md00951g","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
摘要
作为全球发病率和死亡率排名前三的癌症之一,结直肠癌迫切需要新的治疗方法。β-石蜡烯(β-CP)及其衍生物是一类具有广泛抗癌潜力的倍半萜类化合物,本研究对其进行了结构优化,以提高其对结直肠癌的疗效。在所合成的衍生物中,AC-7在HT-29细胞中表现出较强的细胞毒性和选择性(IC50 = 3.09 μM, SI = 6.1),与5-氟尿嘧啶(5-FU, IC50 = 3.63 μM, SI = 0.4)相当。网络药理学和基因富集分析表明,凋亡、自噬、ROS和NF-κB是AC-7的关键下游通路,并在实验中得到验证。AC-7阻滞细胞周期于G0/G1期,促进细胞自噬和凋亡。活性氧被认为在调节这些相关通路中起着核心作用。体内研究显示AC-7在裸鼠模型中具有显著的抗肿瘤和DNA损伤活性。这些发现表明,AC-7通过ros介导的细胞凋亡途径发挥作用,是抗crc治疗的一个有希望的候选者。
Design, synthesis and biological evaluation of novel β-caryophyllene derivatives as potential anti-cancer agents through the ROS-mediated apoptosis pathway†
As a top-three cancer in global incidence and mortality, colorectal cancer (CRC) urgently demands novel treatments. β-Caryophyllene (β-CP) and its derivatives, a class of sesquiterpenoids with broad anticancer potential, were structurally optimized in this study to enhance efficacy against CRC. Among the synthesized derivatives, AC-7 exhibited potent cytotoxicity and selectivity in HT-29 cells (IC50 = 3.09 μM, SI = 6.1), comparable to 5-fluorouracil (5-FU, IC50 = 3.63 μM, SI = 0.4). Network pharmacology and gene enrichment analyses indicated that apoptosis, autophagy, ROS, and NF-κB were key downstream pathways of AC-7, which were later validated experimentally. AC-7 arrested the cell cycle in the G0/G1 phase, promoted autophagy and apoptosis. ROS were identified as having a central role in regulating these related pathways. In vivo studies revealed the significant antitumor and DNA damage activity of AC-7 in a nude mouse model. These findings suggest that AC-7 is a promising candidate for anti-CRC therapy, acting through the ROS-mediated apoptosis pathway.
期刊介绍:
Research and review articles in medicinal chemistry and related drug discovery science; the official journal of the European Federation for Medicinal Chemistry.
In 2020, MedChemComm will change its name to RSC Medicinal Chemistry. Issue 12, 2019 will be the last issue as MedChemComm.